Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia Sells 1,775 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) CFO Sandip Kapadia sold 1,775 shares of the company's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded down $0.87 on Friday, reaching $38.67. 274,698 shares of the company were exchanged, compared to its average volume of 549,018. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The company has a 50-day moving average of $35.20 and a 200-day moving average of $35.22. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same quarter in the prior year, the company earned $0.63 earnings per share. Harmony Biosciences's revenue was up 16.0% compared to the same quarter last year. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on HRMY. Cantor Fitzgerald raised their price target on Harmony Biosciences from $51.00 to $58.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. Needham & Company LLC reaffirmed a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Mizuho lifted their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a report on Thursday, October 10th. Finally, Oppenheimer restated an "outperform" rating and issued a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $55.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Principal Financial Group Inc. grew its stake in shares of Harmony Biosciences by 28.4% in the fourth quarter. Principal Financial Group Inc. now owns 208,663 shares of the company's stock valued at $7,180,000 after buying an additional 46,194 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Harmony Biosciences by 18.0% during the fourth quarter. Rhumbline Advisers now owns 108,588 shares of the company's stock valued at $3,736,000 after purchasing an additional 16,537 shares during the period. New York State Teachers Retirement System grew its holdings in Harmony Biosciences by 2.6% during the 4th quarter. New York State Teachers Retirement System now owns 31,693 shares of the company's stock valued at $1,091,000 after purchasing an additional 809 shares in the last quarter. Legato Capital Management LLC increased its stake in Harmony Biosciences by 26.0% during the 4th quarter. Legato Capital Management LLC now owns 26,720 shares of the company's stock worth $919,000 after buying an additional 5,506 shares during the period. Finally, Louisiana State Employees Retirement System lifted its holdings in Harmony Biosciences by 26.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the company's stock worth $637,000 after buying an additional 3,900 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.